<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189358</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-OVAR 2.6</org_study_id>
    <nct_id>NCT00189358</nct_id>
  </id_info>
  <brief_title>A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy</brief_title>
  <official_title>A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGO Study Group</source>
  <brief_summary>
    <textblock>
      Although initially responsive to cytoreductive surgery and platinum- and/or taxane-based
      chemotherapy, a majority of patients with epithelial ovarian cancer, cancer of the fallopian
      tube or the peritoneum will eventually relapse. Recurrence within 6 months after completing
      platinum-containing chemotherapy indicates a platinum-refractory cancer disease. New
      therapeutic strategies are required in platinum-refractory disease. Inhibition of growth
      signals induced by the epidermal growth factor receptor pathway, or by the estrogen receptor
      pathway provides promising targets in epithelial ovarian cancer, cancer of the fallopian tube
      or the peritoneum. The trial is to evaluate the safety and tolerability of the combination of
      the epidermal growth facto tyrosine kinase inhibitor ZD1839 and the clinically established
      antiestrogen tamoxifen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
  </secondary_outcome>
  <condition>Ovarian Cancer</condition>
  <condition>Cancer of the Fallopian Tube</condition>
  <condition>Peritoneal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD1839</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        histologically confirmed epithelial ovarian cancer, cancer of the fallopian tube or
        peritoneum refractory to platinum- and taxane-based chemotherapy measurable or
        non-measurable disease written informed consent aged 18 years or older Karnofsky
        performance status &gt; 60%

        Exclusion Criteria:

        complete bowel obstruction symptomatic brain metastases known hypersensitivity to evaluated
        drugs inadequate kidney function inadequate hepatic function evidence of clinically active
        interstitial lung disease history of congestive heart failure &gt; NYHA 2
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Wagner, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AGO Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Gynecology, Evangelisches Krankenhaus</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Wagner U, du Bois A, Pfisterer J, Huober J, Loibl S, Lück HJ, Sehouli J, Gropp M, Stähle A, Schmalfeldt B, Meier W, Jackisch C; AGO Ovarian Cancer Study Group. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol. 2007 Apr;105(1):132-7. Epub 2006 Dec 11.</citation>
    <PMID>17161453</PMID>
  </results_reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>July 19, 2010</last_update_submitted>
  <last_update_submitted_qc>July 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2010</last_update_posted>
  <keyword>cancer</keyword>
  <keyword>cancer alternative therapies</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Taxane</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

